Anna Sundlöv
1 – 35 of 35
- show: 250
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Optimal follow-up with somatostatin receptor PET/CT imaging in patients with small intestinal neuroendocrine tumours
2024) In Journal of Neuroendocrinology(
- Contribution to journal › Article
-
Mark
Relationship Between Absorbed Dose and Response in Neuroendocrine Tumors Treated with [177Lu]Lu-DOTATATE
(
- Contribution to journal › Article
-
Mark
Retrospective evaluation of the predictive value of tumour burden at baseline [
68 Ga]Ga-DOTA-TOC or -TATE PET/CT and tumour dosimetry in GEP-NET patients treated with PRRT.
(
- Contribution to journal › Article
- 2023
-
Mark
AI-based quantification of whole-body tumour burden on somatostatin receptor PET/CT
(
- Contribution to journal › Article
-
Mark
Nordic 2023 guidelines for the diagnosis and treatment of lung neuroendocrine neoplasms
(
- Contribution to journal › Scientific review
-
Mark
Phase II study of everolimus and temozolomide as first-line treatment in metastatic high-grade gastroenteropancreatic neuroendocrine neoplasms
(
- Contribution to journal › Article
-
Mark
Germline pathogenic variants in patients with high-grade gastroenteropancreatic neuroendocrine neoplasms
(
- Contribution to journal › Article
- 2022
-
Mark
Relationship between somatostatin receptor expressing tumour volume and health-related quality of life in patients with metastatic GEP-NET
(
- Contribution to journal › Article
-
Mark
Phase II trial demonstrates the efficacy and safety of individualized, dosimetry-based 177Lu-DOTATATE treatment of NET patients
(
- Contribution to journal › Article
-
Mark
Relationships between uptake of [68Ga]Ga-DOTA-TATE and absorbed dose in [177Lu]Lu-DOTA-TATE therapy
(
- Contribution to journal › Article
-
Mark
The molecular characteristics of high-grade gastroenteropancreatic neuroendocrine neoplasms
(
- Contribution to journal › Article
-
Mark
Increased risk of Graves´ophthalmopathy in patients with increasing TRAb after radioiodine treatment and the impact of CTLA4 on TRAb titres
(
- Contribution to journal › Article
-
Mark
Dosimetric quantities of neuroendocrine tumors over treatment cycles with 177Lu-DOTA-TATE
(
- Contribution to journal › Article
- 2021
-
Mark
Pituitary function after high-dose 177Lu-DOTATATE therapy and long-term follow-up
(
- Contribution to journal › Article
-
Mark
Surgery of the primary tumour in 201 patients with high-grade gastroenteropancreatic neuroendocrine and mixed neuroendocrine-non-neuroendocrine neoplasms
(
- Contribution to journal › Article
-
Mark
Impact of Specific Bowel Symptoms on Quality of Life in Patients with Midgut Neuroendocrine Tumours
(
- Contribution to journal › Article
-
Mark
Peptide Receptor Radionuclide Therapy – Prospects for Personalised Treatment
(
- Contribution to journal › Article
- 2020
-
Mark
Tailoring Radionuclide Therapy of Neuroendocrine Tumors - Bridging the Gaps
2020) In Lund University, Faculty of Medicine Doctoral Dissertation Series(
- Thesis › Doctoral thesis (compilation)
-
Mark
Characterisation of a hand-held CZT-based gamma camera for 177Lu imaging
(
- Contribution to journal › Article
- 2019
-
Mark
The Effect of Radioiodine Treatment on TRAb, Anti-TPO, and Anti-TG in Graves' Disease
(
- Contribution to journal › Article
-
Mark
A prospective observational study to evaluate the effects of long-acting somatostatin analogs on 68Ga-DOTATATE uptake in patients with neuroendocrine tumors
(
- Contribution to journal › Article
-
Mark
Bone marrow absorbed doses and correlations with hematological response during 177Lu-DOTATATE treatments are influenced by image-based dosimetry method and presence of skeletal metastases
(
- Contribution to journal › Article
- 2018
-
Mark
A method for tumor dosimetry based on hybrid planar-SPECT/CT images and semiautomatic segmentation
(
- Contribution to journal › Article
-
Mark
Feasibility of simplifying renal dosimetry in 177Lu peptide receptor radionuclide therapy
(
- Contribution to journal › Article
-
Mark
Quantitative analysis of phantom studies of 111In and 68Ga imaging of neuroendocrine tumours
(
- Contribution to journal › Article
-
Mark
Health-Related Quality of Life After Surgery for Small Intestinal Neuroendocrine Tumours
(
- Contribution to journal › Article
- 2017
-
Mark
SPECT image segmentation for estimation of tumour volume and activity concentration in 177Lu-DOTATATE radionuclide therapy
(
- Contribution to journal › Article
-
Mark
Individualised 177Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry
(
- Contribution to journal › Article
- 2015
-
Mark
Long-term retention of 177Lu/177mLu-Dotatate in patients investigated by gamma spectrometry and gamma camera imaging.
(
- Contribution to journal › Article
- 2014
-
Mark
Nordic guidelines 2014 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms
(
- Contribution to journal › Scientific review
- 2011
-
Mark
The role of RANK-ligand inhibition in cancer : the story of denosumab
(
- Contribution to journal › Scientific review
- 2006
-
Mark
Treatment options for colorectal cancer in the elderly
(
- Contribution to journal › Scientific review
-
Mark
Docetaxel and mitomycin as second-line treatment in advanced non-small cell lung cancer
(
- Contribution to journal › Article
-
Mark
Bacteriemia por Acinetobacter ursingii
(
- Contribution to journal › Letter
- 2004
-
Mark
Anticuerpos contra el cáncer
(
- Contribution to journal › Scientific review